hit counter
Aceto Corporation (ACET) Stock News Sentiment & Price - Sentifly
ACET - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Aceto Corporation (ACET)

USA
Chemicals - Major Diversified
NASDAQ
ACET Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ACET Latest news
Zacks Investment Research
Negative
Adicet Bio, Inc. (ACET) Reports Q3 Loss, Lags Revenue Estimates
2021-11-10 19:05

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -15.79% and -26.26%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire
Neutral
Adicet Reports Third Quarter 2021 Financial Results and Provides Business Updates
2021-11-10 16:01

MENLO PARK, Calif. and BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today reported operational highlights and financial results for the third quarter ended September 30, 2021.

GlobeNewsWire
Neutral
Adicet Bio to Participate in Stifel 2021 Virtual Healthcare Conference
2021-11-08 07:00

MENLO PARK, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference taking place on November 15-17, 2021.

GlobeNewsWire
Neutral
Adicet Announces Trials in Progress Poster Presentation for ADI-001 at 2021 ASH Annual Meeting
2021-11-04 09:00

MENLO PARK, Calif. and BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that a Trials in Progress abstract related to the Company's lead candidate, ADI-001, has been accepted for an oral presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 11-14, 2021.

GlobeNewsWire
Neutral
CDR-Life Announces Expansion of Scientific Advisory Board
2021-10-26 03:00

Two renowned experts join to advise CDR-Life as the company advances pipeline of novel cancer therapeutic candidates Two renowned experts join to advise CDR-Life as the company advances pipeline of novel cancer therapeutic candidates

GlobeNewsWire
Neutral
Adicet Announces Promotion of Blake Aftab, Ph.D. to Chief Scientific Officer
2021-10-12 16:10

MENLO PARK, Calif. and BOSTON, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced Blake Aftab, Ph.D., has been promoted to the position of Senior Vice President and Chief Scientific Officer. In this role, Dr. Aftab will be responsible for the continued expansion of Adicet's pipeline of therapeutic candidates in solid and hematologic tumors.

GlobeNewsWire
Neutral
Adicet to Present Preclinical Data from Allogeneic Gamma Delta T Cell Platform at SITC 36th Annual Meeting
2021-10-04 07:00

MENLO PARK, Calif. and BOSTON, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the Company will present data in the form of a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting to be held November 10-14, 2021.

GlobeNewsWire
Neutral
Adicet Bio to Participate in Upcoming Investor Conferences
2021-09-02 16:53

MENLO PARK, Calif. and BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in two upcoming virtual investor conferences in September.

Zacks Investment Research
Positive
Adicet Bio, Inc. (ACET) Reports Q2 Loss, Tops Revenue Estimates
2021-08-12 19:19

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 33.33% and 6.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire
Neutral
Adicet Reports Second Quarter 2021 Financial Results and Provides Business Updates
2021-08-12 16:01

On track to report top-line interim data from ADI-001 Phase 1 study in Non-Hodgkin's Lymphoma (NHL) by the end of 2021 On track to report top-line interim data from ADI-001 Phase 1 study in Non-Hodgkin's Lymphoma (NHL) by the end of 2021

Loading more news...